These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 19692382)
1. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382 [TBL] [Abstract][Full Text] [Related]
2. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Tabbara KF; Al-Hemidan AI Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466 [TBL] [Abstract][Full Text] [Related]
6. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Galor A; Perez VL; Hammel JP; Lowder CY Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958 [TBL] [Abstract][Full Text] [Related]
8. [The treatment of recurrent uveitis with TNF-alpha inhibitors]. Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524 [TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389 [TBL] [Abstract][Full Text] [Related]
10. Infliximab in the treatment of refractory posterior uveitis. Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408 [TBL] [Abstract][Full Text] [Related]
11. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623 [TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Tognon S; Graziani G; Marcolongo R Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463 [TBL] [Abstract][Full Text] [Related]
13. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502 [TBL] [Abstract][Full Text] [Related]
14. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Okada AA; Goto H; Ohno S; Mochizuki M; Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Markomichelakis N; Delicha E; Masselos S; Sfikakis PP Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563 [TBL] [Abstract][Full Text] [Related]
16. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Keino H; Okada AA; Watanabe T; Taki W Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514 [TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187 [TBL] [Abstract][Full Text] [Related]
18. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769 [TBL] [Abstract][Full Text] [Related]
19. Retrospective case review of pediatric patients with uveitis treated with infliximab. Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545 [TBL] [Abstract][Full Text] [Related]
20. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease. Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]